What question did this study set out to answer?

To review the long-term clinical sequelae, relapse patterns, and post-remission care strategies for patients surviving immune thrombotic thrombocytopenic purpura (iTTP).

June 7, 2025Transfusion and Apheresis ScienceOpen Access

Relapse and beyond: Navigating the long-term clinical impacts of immune thrombotic thrombocytopenic purpura

View Full Paper

Ask AI

Bookmark

Authors

MTMinh‐Ha TranUniversity of California, Irvine JJJennifer JonesUniversity of Maryland, Baltimore JQJesse QiaoUniversity of California, Irvine

Discussion

Member takes

Overview

Narrative review highlights chronic neurological, cardiovascular, and psychological complications in immune thrombotic thrombocytopenic purpura survivors, indicating a need for multidisciplinary care.

Key Points

To review the long-term clinical sequelae, relapse patterns, and post-remission care strategies for patients surviving immune thrombotic thrombocytopenic purpura (iTTP).
Synthesized findings from a narrative review of clinical literature covering acute management, long-term morbidity, and surveillance strategies in iTTP.
Evaluated post-remission outcomes including persistent ADAMTS13 deficiency, relapse monitoring, and multidisciplinary care models.
Survivors of iTTP frequently endure chronic cognitive impairment, elevated risks for hypertension and arterial ischemic events, and significant mental health morbidities such as depression and anxiety.
Persistent ADAMTS13 deficiency indicates an ongoing risk of relapse, underscoring the necessity of proactive longitudinal monitoring and individualized preemptive therapy.

Cite This Study

Tran et al. (2025) studied this question.

synapsesocial.com/papers/6a9fe7f025a538586e5cc312 https://doi.org/10.1016/j.transci.2025.104174

View Full Paper

Ask AI

Bookmark

June 7, 2025Transfusion and Apheresis ScienceOpen Access

Relapse and beyond: Navigating the long-term clinical impacts of immune thrombotic thrombocytopenic purpura

View Full Paper

Ask AI

Bookmark

Authors

MTMinh‐Ha TranUniversity of California, Irvine JJJennifer JonesUniversity of Maryland, Baltimore JQJesse QiaoUniversity of California, Irvine

Discussion

Member takes

Overview

Key Points

To review the long-term clinical sequelae, relapse patterns, and post-remission care strategies for patients surviving immune thrombotic thrombocytopenic purpura (iTTP).
Synthesized findings from a narrative review of clinical literature covering acute management, long-term morbidity, and surveillance strategies in iTTP.
Evaluated post-remission outcomes including persistent ADAMTS13 deficiency, relapse monitoring, and multidisciplinary care models.
Survivors of iTTP frequently endure chronic cognitive impairment, elevated risks for hypertension and arterial ischemic events, and significant mental health morbidities such as depression and anxiety.
Persistent ADAMTS13 deficiency indicates an ongoing risk of relapse, underscoring the necessity of proactive longitudinal monitoring and individualized preemptive therapy.

Cite This Study

Tran et al. (2025) studied this question.

synapsesocial.com/papers/6a9fe7f025a538586e5cc312 https://doi.org/10.1016/j.transci.2025.104174

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark